Flagyl 0.5%w/v Solution for Infusion in Viaflex Container
- Name:
Flagyl 0.5%w/v Solution for Infusion in Viaflex Container
- Company:
SANOFI
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 12/03/19
(Click to Download)Click on this link to Download PDF directly
SANOFI
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 12 March 2019 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
Updated on 20 July 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
Updated on 20 July 2018 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
- Special warnings and special precautions for use
Wording replaced in paragraph with:-
- (SJS),
- (TEN) or acute generalised exanthematous pustulosis (AGEP)
- AGEP
- must be immediately
- Undesirable effects
Skin and subcutaneous tissue disorders
Wording added into paragragh
- acute generalised exanthematous pustulosis
Updated on 22 December 2016 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 22 December 2016 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 20 December 2016 PIL
Reasons for updating
- New PIL for new product
Updated on 20 December 2016 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Updated on 30 August 2016 PIL
Reasons for updating
- Change to side-effects
Updated on 19 August 2016 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.8 Undesirable effects
Frequency, type and severity of adverse reactions in children are the same as in adults.
Gastrointestinal disorders
- epigastric pain, nausea, vomiting, malaise, diarrhoea.
- oral mucositis, taste disorders, dry mouth, anorexia.
- reversible cases of pancreatitis.
- tongue discolouration/furry tongue.
Immune system disorders
- angioedema, anaphylactic shock.
Nervous system disorders
- peripheral sensory neuropathy, paraesthesia
- headache, convulsions, dizziness.
- reports of encephalopathy (e.g. confusion) and subacute cerebellar syndrome (e.g. ataxia, dysathria, gait impairment, nystagmus and tremor) which may resolve with discontinuation of the drug.
- aseptic meningitis
Psychiatric disorders
- psychotic disorders including confusion, hallucinations
- depressed mood
Eye disorders
- transient vision disorders such as diplopia, myopia, blurred vision, decreased visual acuity, changes in color vision.
- Optic neuropathy/neuritis.
Ear and labyrinth disorders
- hearing impaired/hearing loss (including sensorineural)
- tinnitus
Blood and lymphatic system disorders
- cases of agranulocytosis, neutropenia and thrombocytopenia have been reported.
Hepatobiliary disorders
- increase in liver enzymes (AST, ALT, alkaline phosphatase), cholestatic or mixed hepatitis and hepatocellular liver injury, sometimes with jaundice, have been reported.
- cases of liver failure requiring liver transplant have been reported in patients treated with metronidazole mostly when used in combination with other antibiotic drugs.
Skin and subcutaneous tissue disorders
- rash, pruritus, flushing, urticaria
- pustalar eruptions
- fixed drug eruption
- Stevens-Johnson syndrome, toxic epidermal necrolysis.
General disorders and administration site conditions
- fever
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRAPharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; e-mail: medsafety@hpra.ie
Updated on 4 April 2014 PIL
Reasons for updating
- Change to side-effects
Updated on 19 March 2014 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 27 June 2013 PIL
Reasons for updating
- Change to marketing authorisation holder
Updated on 5 March 2013 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 28 February 2013 PIL
Reasons for updating
- Improved electronic presentation
Updated on 29 August 2012 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 14 December 2011 SmPC
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 5.3 - Preclinical safety data
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
CSDS Update & Article 45
Updated on 10 September 2009 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 4 April 2008 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 2 April 2008 SmPC
Reasons for updating
- Correction of spelling/typing errors
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 10 March 2008 SmPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 23 November 2006 SmPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Product subject to medical prescription which may not be renewed (A)